TY - JOUR
T1 - Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in TWN
T2 - A prospective observational study
AU - Tsai, Tsen Fang
AU - Yao, Chien An
AU - Yu, Hsin Su
AU - Lan, Cheng Che
AU - Chao, Sheau Chiou
AU - Yang, Jen Hung
AU - Yang, Kuo Chia
AU - Chen, Ching Yu
AU - White, Ron R.
AU - Psaradellis, Eliofotisti
AU - Rampakakis, Emmanouil
AU - Kawai, Kosuke
AU - Acosta, Camilo J.
AU - Sampalis, John S.
N1 - Publisher Copyright:
© 2014 The International Society of Dermatology.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Background: To assess the severity and duration of herpes zoster (HZ)-associated pain (ZAP) and its impact on quality of life (QoL) and healthcare utilization (HCRU) from a patient perspective in routine care in TWN. Methods: A prospective, observational, single-cohort study was conducted in five centers across TWN. Patients were recruited at different time points during their HZ episode and were followed for ≤180 days. ZAP was assessed with the Initial Zoster Impact Questionnaire and the Zoster Brief Pain Inventory, QoL with the EQ-5D, and HCRU with a simple questionnaire. Results: A total of 150 patients were included with a mean age of 64.9 years and mean time since rash onset of 18.8 days. Prodromal pain was experienced by 64.7% of patients, of whom 91.8% reported moderate-to-severe pain. At enrollment, 98.0% of patients experienced ZAP. Mean ± SD worst pain score decreased from 5.95 ± 3.09 at enrollment to 2.65 ± 2.98 at 30 days and 0.28 ± 0.83 at 180 days. Postherpetic neuralgia was observed in 20.7% of patients. Mean ± SD EQ-5D score significantly decreased (P < 0.001) from 0.91 ± 0.16 before rash onset to 0.67 ± 0.18 after rash onset, showing significant QoL deterioration up to 60 days. The impact of HZ on QoL and pain severity was similar across age groups. Significant HCRU was observed including visits to the doctor (83.3% of patients), specialist (30.7%), emergency department (24.7%), physiotherapist (23.3%), and hospitalizations (20.7%). Conclusion: Severe morbidity and significant HCRU are associated with HZ in TWN, supporting the need for early intervention and preventive strategies to reduce the HZ-associated burden of illness.
AB - Background: To assess the severity and duration of herpes zoster (HZ)-associated pain (ZAP) and its impact on quality of life (QoL) and healthcare utilization (HCRU) from a patient perspective in routine care in TWN. Methods: A prospective, observational, single-cohort study was conducted in five centers across TWN. Patients were recruited at different time points during their HZ episode and were followed for ≤180 days. ZAP was assessed with the Initial Zoster Impact Questionnaire and the Zoster Brief Pain Inventory, QoL with the EQ-5D, and HCRU with a simple questionnaire. Results: A total of 150 patients were included with a mean age of 64.9 years and mean time since rash onset of 18.8 days. Prodromal pain was experienced by 64.7% of patients, of whom 91.8% reported moderate-to-severe pain. At enrollment, 98.0% of patients experienced ZAP. Mean ± SD worst pain score decreased from 5.95 ± 3.09 at enrollment to 2.65 ± 2.98 at 30 days and 0.28 ± 0.83 at 180 days. Postherpetic neuralgia was observed in 20.7% of patients. Mean ± SD EQ-5D score significantly decreased (P < 0.001) from 0.91 ± 0.16 before rash onset to 0.67 ± 0.18 after rash onset, showing significant QoL deterioration up to 60 days. The impact of HZ on QoL and pain severity was similar across age groups. Significant HCRU was observed including visits to the doctor (83.3% of patients), specialist (30.7%), emergency department (24.7%), physiotherapist (23.3%), and hospitalizations (20.7%). Conclusion: Severe morbidity and significant HCRU are associated with HZ in TWN, supporting the need for early intervention and preventive strategies to reduce the HZ-associated burden of illness.
UR - http://www.scopus.com/inward/record.url?scp=84928325439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928325439&partnerID=8YFLogxK
U2 - 10.1111/ijd.12484
DO - 10.1111/ijd.12484
M3 - Article
C2 - 25209019
AN - SCOPUS:84928325439
SN - 0011-9059
VL - 54
SP - 529
EP - 536
JO - International Journal of Dermatology
JF - International Journal of Dermatology
IS - 5
ER -